Prostate Cancer: Related News

On Our Blog

Solutions for Chemotherapy-Related Nausea and Vomiting

With quick action and the help of the right medicine at the right time, chemotherapy-induced nausea and vomiting can often be prevented, says MSK Nurse Leader Corey Russell.

September 29, 2014
Prostate Cancer Organoids Provide New Tool for Evaluating Therapies

Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.

September 4, 2014
Pictured: Michael Zelefsky
Treating Prostate Cancer with a Missile-Like Delivery of High-Dose Radiation

Memorial Sloan Kettering offers patients with prostate cancer a comprehensive package of the most advanced radiation therapy approaches that enable more-personalized and effective care.

October 23, 2013
Pictured: Vincent Laudone and James Eastham
When "Do No Harm" Means "Do Nothing": Managing Risks

An earlier post about active surveillance as a management strategy for prostate cancer generated an engaged and meaningful discussion on this blog, especially about the risks of “doing nothing.” Here we take a closer look at the concept of risk.

September 20, 2013
Pictured: Vincent Laudone  & James Eastham
When “Do No Harm” Means “Do Nothing”

Active surveillance is the most appropriate management strategy for many men with prostate cancer, but often this option is never mentioned.

August 14, 2013
Pictured: Pramod Sogani
Pramod Sogani Inaugurated As President of the American Urological Association

Memorial Sloan Kettering urologic surgeon Pramod Sogani has been inaugurated as President of the American Urological Association. In this Q&A he discusses his goals and his new role.

July 1, 2013
Charles Sawyers, Kenneth Offit, and Larry Norton
Three Memorial-Sloan Kettering Researchers Receive Special Awards by the American Society of Clinical Oncology

Charles Sawyers, Larry Norton, and Kenneth Offit are being honored with special awards at the annual meeting of the world’s leading professional organization for cancer physicians and researchers.

May 22, 2013
Pictured: Charles Sawyers
Research Suggests a New Approach for Overcoming Resistance to a Targeted Therapy for Prostate Cancer

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

April 30, 2013
Pictured: Andrew Vickers
A Single Early PSA Test Found to Predict Long-Term Risk of Aggressive Prostate Cancer

A study led by Memorial Sloan Kettering investigators indicates nearly half of all prostate cancer deaths by age 75 occur in a small group of men with high PSA levels at age 45.

April 17, 2013
Pictured: Peter Scardino
Department of Surgery Chair Peter Scardino on Smarter Screening for Prostate Cancer

Dr. Scardino discusses strategies for how physicians and patients can make the best use of PSA testing and prostate cancer treatment.

March 14, 2013
Pictured: John Mulhall
Urologist John Mulhall Explains Strategies for Addressing Sexual Health Concerns for Men with Cancer

Dr. Mulhall, director of Memorial Sloan Kettering’s Male Sexual and Reproductive Medicine Program, explains common concerns about male sexual health and offers advice for men and their partners.

March 8, 2013
Pictured: Raul Parra
Meet Urologic Cancer Surgeon Raul Parra

Dr. Parra, who practices at Memorial Sloan Kettering Basking Ridge, treats prostate, kidney, and bladder cancers with the goal of extending the lives of patients, and giving them the best possible quality of life.

March 6, 2013
Pictured: David Finley & Maria Teresa Ruiz Tsukazan
Robot-Assisted Surgery at Memorial Sloan Kettering

Our doctors introduce and apply advanced technologies in minimal-access surgery to benefit patients.

February 25, 2013
Pictured: Bernard Bochner
Meet Urologic Surgeon Bernard Bochner

Dr. Bochner – who specializes in treating people with prostate, bladder, and kidney cancers – discusses the importance of a multidisciplinary team approach to delivering high-quality care.

January 11, 2013
Pictured: Michael Zelefsky
Medication Used Before, During, and After Radiation Treatment Helps Men with Prostate Cancer Maintain Overall Sexual Function

Study signals hope for maintaining sexual function in men undergoing radiation treatment for prostate cancer.

November 30, 2012
Pictured: PET Scan
New Imaging Agent Could Improve Prostate Cancer Diagnosis and Treatment

Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

November 15, 2012
Pictured: Charles Sawyers & Howard Scher
Targeted Therapy for Advanced Prostate Cancer Receives FDA Approval

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

August 31, 2012
Pictured: Karim Touijer
Meet Urologic Surgeon Karim Touijer

Watch urologic surgeon Karim Touijer discuss our comprehensive approach to cancer care and recent advances in minimally invasive surgery.

July 31, 2012
Pictured: Howard Scher
Memorial Sloan Kettering Experts Maintain That PSA Screening for Prostate Cancer Saves Lives

Memorial Sloan Kettering’s prostate cancer team — including Howard I. Scher, Chief of the Genitourinary Oncology Service — disagrees with new PSA screening recommendations released by government task force.

June 1, 2012
Pictured: American Association of Cancer Research Annual Meeting 2012
Memorial Sloan Kettering Discoveries in Personalized Medicine Highlighted at Major Cancer Research Meeting; Investigators Honored

The American Association for Cancer Research (AACR), the world’s oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.

April 3, 2012
Pictured: Peter Scardino
Surgery’s Vital Role in Treating Cancer

Department of Surgery Chair Peter T. Scardino reflects on the expanding role of surgery at an institution devoted to caring for people with cancer.

March 12, 2012
Pictured: Memorial Sloan Kettering logo
Memorial Sloan Kettering Made Major Contributions to Cancer Advances in 2011

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

February 6, 2012
Pictured: Charles Sawyers & Howard Scher
New Medical Strides against Prostate Cancer

The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.

February 3, 2012
Pictured: Michael Morris
Bone Scan Index May Help Determine Response to Prostate Cancer Treatment

Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.

January 13, 2012
Pictured: Charles Sawyers & Howard Scher
Positive Results in Clinical Trial for Advanced Prostate Cancer Drug

A late-stage clinical trial of a drug for advanced prostate cancer was stopped this week after it was found to extend survival by nearly five months.

November 4, 2011
Brett Carver
Memorial Sloan Kettering Researchers Discover How Prostate Cancer Disease Pathways Regulate Each Other

Memorial Sloan Kettering researchers have discovered that the AR and PI3K disease pathways regulate each other through reciprocal negative feedback.

July 1, 2011
Pictured: Jedd Wolchok & Paul Chapman
Memorial Sloan Kettering Physician-Scientists Present Significant Clinical Cancer Research Advances at ASCO Annual Meeting

In an extraordinary demonstration of excellence, five Memorial Sloan Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.

July 1, 2011
Pictured: Andrew Vickers
Using Finasteride to Prevent Prostate Cancer

The drug finasteride, used to treat benign enlargement of the prostate, has been shown in a large, randomized study to prevent prostate cancer, reducing the risk of the disease by close to 25 percent. However, the drug is not widely used as a preventive, which experts attribute to the modest benefit it offers to the average man. In a recent analysis of the data from the original study, investigators from Memorial Sloan Kettering Cancer Center have found that finasteride is best given only to men at higher than average risk of getting prostate cancer.

April 1, 2010
Charles Sawyers (left) and Howard Scher
Advances in Development of New Targeted Therapy for Prostate Cancer Show Promise

A team of researchers led by Memorial Sloan Kettering physician-scientist Charles L. Sawyers has reported on the preclinical development and early results from the first clinical trial of a promising new drug for prostate cancer.

July 1, 2009

Related Media Coverage

Custom-Fit Treatments for Prostate Cancer

Research led by radiation oncologist William Polkinghorn and physician-scientist Charles Sawyers suggests that analyzing a tumor’s DNA may identify prostate cancer patients who would benefit from radiation alone or in combination with other treatments.

January 14, 2014
New Debate on Prostate Cancer Drug

Prostate cancer surgeon Peter Scardino weighed in on a new study that has reignited a debate about whether men should use a baldness drug to prevent prostate cancer.

August 15, 2013
Urology Group Stops Recommending Routine PSA Test

Prostate cancer surgeon Peter Scardino commented on new PSA screening guidelines released by the American Urological Association.

May 3, 2013
Obesity Increases Men's Risk of Dying from Prostate Cancer

Epidemiologist Helena Furberg commented on a study that found that men who are overweight are more likely to have precancerous lesions detected in a benign prostate biopsy and are at a greater risk for subsequently developing prostate cancer.

April 23, 2013
Pared Back Prostate Cancer Screening May Save Lives

A study led by epidemiologist Andrew Vickers found that certain men may need only three PSA tests in their lifetime.

April 17, 2013
Cancer Diagnosis: Less Can Be More

Prostate cancer surgeon Peter Scardino was interviewed about prostate cancer screening tests.

March 26, 2013
Surgery Restoring Penis after Prostate Cancer Increasing

Director of Memorial Sloan Kettering’s Male Sexual and Reproductive Medicine Program John Mulhall discussed ways to improve sexual function after prostate cancer surgery.

March 25, 2013
Men Have More Options in Prostate Cancer Treatments

Medical oncologist Howard Scher commented on the growing arsenal of prostate cancer treatments.

October 1, 2012
Targeted Therapy Improves Overall Survival in Men with Late-Stage Prostate Cancer

The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer, results of a large, phase III study show.

January 31, 2012
Drug Shown To Significantly Improve Survival In Men With Metastatic Prostate Cancer While Exploring A Potential Biomarker To Measure Treatment Response

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.

June 4, 2011
Drug Shown to Improve Overall Survival in Patients with Metastatic Prostate Cancer

An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute of Cancer Research and the Royal Marsden Hospital in the UK as well as other cancer centers around the world published the findings in the May 26, 2011, issue of The New England Journal of Medicine.

May 25, 2011
Blood Test Given Earlier Than Recommended Predicts Long-Term Risk of Death from Prostate Cancer and Suggests Annual PSA Testing for Most Men is Unnecessary

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

May 19, 2011
Change in PSA Level Does Not Predict Prostate Cancer

Researchers at Memorial Sloan Kettering Cancer Center have found that change in PSA levels over time - known as PSA velocity - is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.

February 24, 2011
Blood Test Accurately Predicts Death from Prostate Cancer up to 25 Years in Advance

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the British Medical Journal.

September 14, 2010
Large-Scale Genomic Analysis of Prostate Cancer Unveiled

A unique collaboration among physician-scientists at Memorial Sloan Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. The study, published in the journal Cancer Cell, provides a previously unavailable genomic analysis whose scope and size offers new insight leading to more effective diagnostic tests as well as future treatment options for prostate cancer patients.

June 24, 2010
Charles Sawyers (left) and Howard Scher
New Targeted Therapy Effective in Treating Advanced Prostate Cancer

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

April 14, 2010
Prostate Cancer Surgery Often Performed by Surgeons with Little Experience

A new study from researchers at Memorial Sloan Kettering Cancer Center has found that the majority of surgeons treating prostate cancer in the United States have extremely low annual caseloads, potentially leading to increased rates of both surgical complications and cancer recurrence.

November 18, 2009
In the Modern Post-PSA Era, Prostate Cancer Surgery May Not be Necessary for Some Patients

Investigators at Memorial Sloan Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

July 27, 2009
Drug Shows Activity in Men with Advanced Prostate Cancer

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels - a marker for tumor growth - in men with advanced prostate cancer for whom traditional treatment options have failed.

April 9, 2009
Hans G. Lilja
PSA Testing Can Predict Advanced Prostate Cancer

A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan Kettering Cancer Center in New York and Lund University in Sweden.

February 14, 2008
Peter T. Scardino, MD
Outcome of Prostate Cancer Surgery Depends on the Experience of the Surgeon

According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.

July 24, 2007